FFM
ASND icon

Fairmount Funds Management’s Ascendis Pharma A/S ASND Stock Holding History

Fairmount Funds Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-29,676
Closed -$4.13M – 15
2019
Q4 		$4.13M Buy
+29,676
New +$3.3M 2.5% 11

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fairmount Funds Management's ASND Position: Q1 2020 in Review

Fairmount Funds Management sold out of Ascendis Pharma A/S (ASND) in Q1 2020, closing a stake of 29,676 shares — an estimated $4.13M sold.

Fairmount Funds Management first reported a position in ASND in Q4 2019 and held it in 1 quarter. The position peaked at $4.13M in Q4 2019. 147 funds tracked by Wall St. Rank hold ASND as of Q1 2020.

  • Fairmount Funds Management reported no remaining Ascendis Pharma A/S position as of Q1 2020 after selling out during the quarter.
  • Fairmount Funds Management sold 29,676 Ascendis Pharma A/S shares in Q1 2020, an estimated $4.13M.
  • Fairmount Funds Management first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 1 quarter.
  • Fairmount Funds Management's Ascendis Pharma A/S position peaked at $4.13M in Q4 2019.
  • 147 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2020.

Based on Fairmount Funds Management's 13F filing for Q1 2020, filed 8 May 2020.